{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T16:26:57Z","timestamp":1787416017982,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["2019007"],"award-info":[{"award-number":["2019007"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["2024077"],"award-info":[{"award-number":["2024077"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejca.2026.116940","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:16:15Z","timestamp":1783700175000},"page":"116940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Risk of recurrence of stage I to III melanoma in Norway, 2008\u20132022"],"prefix":"10.1016","volume":"245","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8623-9886","authenticated-orcid":false,"given":"Anastasia","family":"Giorcelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7992-5023","authenticated-orcid":false,"given":"Morten","family":"Valberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2753-4841","authenticated-orcid":false,"given":"Adele C.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2083-2758","authenticated-orcid":false,"given":"Marit B.","family":"Veier\u00f8d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6533-7905","authenticated-orcid":false,"given":"Denise R.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon Michael","family":"Gran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik L.","family":"Svendsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Jespersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5087-2913","authenticated-orcid":false,"given":"Bettina K.","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-7734","authenticated-orcid":false,"given":"Trude E.","family":"Robsahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5466-7308","authenticated-orcid":false,"given":"Reza","family":"Ghiasvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116940_bib1","article-title":"Global cancer observatory: cancer today","author":"Ferlay","year":"2024","journal-title":"Cancer IAfRo Editor"},{"key":"10.1016\/j.ejca.2026.116940_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2026.116940_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrc1781","article-title":"Predicting the future burden of cancer","volume":"6","author":"Bray","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2026.116940_bib4","series-title":"Global cancer observatory: cancer tomorrow (version 1.1)","author":"Ferlay","year":"2024"},{"key":"10.1016\/j.ejca.2026.116940_bib5","first-page":"41266","article-title":"From trials to practice: immune checkpoint inhibitor therapy for Melanoma patients in Norway","volume":"63","author":"Costa","year":"2024","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2026.116940_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2026.116940_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051514","article-title":"Melanoma mortality trends in 28 European countries: a retrospective analysis for the years 1960-2020","volume":"15","author":"Koczkodaj","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2026.116940_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(23)00646-0","article-title":"Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study","volume":"25","author":"De Angelis","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116940_bib9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jso.20079","article-title":"The natural course of cutaneous melanoma","volume":"86","author":"Leiter","year":"2004","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116940_bib10","unstructured":"FHI. Nasjonalt kvalitetsregister for melanom: \u00c5rsrapport 2024. 2025."},{"key":"10.1016\/j.ejca.2026.116940_bib11","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1470-2045(05)70283-7","article-title":"Follow-up in patients with localised primary cutaneous melanoma","volume":"6","author":"Francken","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116940_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bjd.12687","article-title":"Comparison of melanoma guidelines in the USA, Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review","volume":"170","author":"Fong","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116940_bib13","article-title":"Follow-up schedule for patients with sentinel node\u2013negative cutaneous melanoma (The MELFO Study): an international phase III randomized clinical trial","author":"Moncrieff","year":"2022","journal-title":"LWW"},{"key":"10.1016\/j.ejca.2026.116940_bib14","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1002\/cam4.2252","article-title":"Melanoma incidence, recurrence, and mortality in an integrated healthcare system: a retrospective cohort study","volume":"8","author":"Feigelson","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2026.116940_bib15","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1002\/ijc.30407","article-title":"Epidemiology of cutaneous melanoma in Sweden\u2014stage-specific survival and rate of recurrence","volume":"139","author":"Rockberg","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2026.116940_bib16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1200\/JCO.2006.08.1463","article-title":"Identification of high-risk patients among those diagnosed with thin cutaneous melanomas","volume":"25","author":"Gimotty","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116940_bib17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00268-010-0859-8","article-title":"Malignant melanoma of the skin: long-term follow-up and time to first recurrence","volume":"35","author":"Hohnheiser","year":"2011","journal-title":"World J Surg"},{"key":"10.1016\/j.ejca.2026.116940_bib18","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jamadermatol.2019.0440","article-title":"Risk of melanoma recurrence after diagnosis of a high-risk primary tumor","volume":"155","author":"Von Schuckmann","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2026.116940_bib19","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.amjsurg.2010.07.025","article-title":"Risk factors associated with local and in-transit recurrence of cutaneous melanoma","volume":"200","author":"Stucky","year":"2010","journal-title":"Am J Surg"},{"key":"10.1016\/j.ejca.2026.116940_bib20","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2023.3256","article-title":"Stage-specific risk of recurrence and death from Melanoma in Denmark, 2008-2021: a National Observational Cohort Study of 25\u00a0720 Patients With Stage IA to IV Melanoma","volume":"159","author":"Helvind","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2026.116940_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1590\/abd1806-4841.20184779","article-title":"Prognostic factors for metastasis in cutaneous melanoma","volume":"93","author":"Cherobin","year":"2018","journal-title":"Bras De Dermatol"},{"key":"10.1016\/j.ejca.2026.116940_bib22","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1245\/s10434-023-14724-5","article-title":"Factors affecting recurrence and survival for patients with high-risk stage II Melanoma","volume":"31","author":"Dedeilia","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2026.116940_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2026.0001","article-title":"Clinical and pathologic factors in stage I and II Melanoma recurrence","author":"Mundada","year":"2026","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2026.116940_bib24","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1001\/jama.2024.4970","article-title":"Accounting for competing risks in clinical research","volume":"331","author":"Austin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2026.116940_bib25","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Association WM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2026.116940_bib26","doi-asserted-by":"crossref","DOI":"10.4178\/epih\/e2011005","article-title":"Quality of cohort studies reporting post the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement","volume":"33","author":"Poorolajal","year":"2011","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.ejca.2026.116940_bib27","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.ejca.2008.10.037","article-title":"Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness","volume":"45","author":"Larsen","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116940_bib28","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ejca.2026.116940_bib29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2147\/CLEP.S151246","article-title":"High mortality due to cutaneous melanoma in Norway: a study of prognostic factors in a nationwide cancer registry","author":"Robsahm","year":"2018","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ejca.2026.116940_bib30","doi-asserted-by":"crossref","unstructured":"Rebora P., Salim A., Reilly M. Bshazard: a flexible tool for nonparametric smoothing of the hazard function. 2014.","DOI":"10.32614\/RJ-2014-028"},{"key":"10.1016\/j.ejca.2026.116940_bib31","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/17469872.3.5.569","article-title":"Current concepts of metastasis in melanoma","volume":"3","author":"Zbytek","year":"2008","journal-title":"Expert Rev Dermatol"},{"key":"10.1016\/j.ejca.2026.116940_bib32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2026.116940_bib33","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1200\/JCO.2004.12.015","article-title":"Thin Primary Cutaneous Malignant Melanoma: a prognostic tree for 10-year Metastasis is more accurate than American Joint Committee on Cancer Staging","volume":"22","author":"Gimotty","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116940_bib34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ejca.2026.116940_bib35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.sla.0000216771.81362.6b","article-title":"Gender-related differences in outcome for melanoma patients","volume":"243","author":"Scoggins","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2026.116940_bib36","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/bjd.19601","article-title":"Patient age and risk of recurrence of primary melanoma at high risk of spread","volume":"184","author":"Ghiasvand","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2026.116940_bib37","unstructured":"Helsedirectoratet. Helsedirectoratet. Malignt melanom - Pakkeforl\u00f8p, https:\/\/www.helsedirektoratet.no\/nasjonale-forlop\/foflekkreft; 2022 [accessed 4 April 2025]."},{"key":"10.1016\/j.ejca.2026.116940_bib38","unstructured":"Helsedirectoratet. Malignt melanom - Handlingsplan, https:\/\/www.helsedirektoratet.no\/nasjonale-forlop\/foflekkreft; 2022 [accessed 4 April 2025]."},{"key":"10.1016\/j.ejca.2026.116940_bib39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/CLEP.S295844","article-title":"A validated register-based algorithm to identify patients diagnosed with recurrence of malignant melanoma in Denmark","author":"Rasmussen","year":"2021","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ejca.2026.116940_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2026.103067","article-title":"European expert consensus on cancer recurrence and progression data collection by population based cancer registries","volume":"102","author":"Hawkins","year":"2026","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.ejca.2026.116940_bib41","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1186\/s12889-025-23926-3","article-title":"The impact of the COVID-19 pandemic on melanoma diagnosis: a systematic review and meta-analysis of global evidence","volume":"25","author":"Mostafavi Zadeh","year":"2025","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ejca.2026.116940_bib42","unstructured":"Brenn H.H., Robsahm T.E., D\u00f8rum L.M., Svendsen H.L. The national quality register for melanoma helps to strengthen the quality of healthcare provided to melanoma patients. 2023."},{"key":"10.1016\/j.ejca.2026.116940_bib43","doi-asserted-by":"crossref","DOI":"10.1007\/s10654-013-9873-0","article-title":"When the entire population is the sample: strengths and limitations in register-based epidemiology","volume":"29","author":"Thygesen","year":"2014","journal-title":"Eur J Epidemiol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926007215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T16:20:52Z","timestamp":1787415652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926007215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"alternative-id":["S0959804926007215"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116940","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of recurrence of stage I to III melanoma in Norway, 2008\u20132022","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116940"}}